Cytotoxic Activity of Isoniazid Derivative in Human Breast Cancer Cells
Autor: | Vanitha Mariappan, Kumutha Malar Vellasamy, Zaridatul Aini Ibrahim, Jamuna Vadivelu, Naveen Kumar Hawala Shivashekaregowda, Ahmad Khusairy Zulpa, Muttiah Barathan |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Pharmacology
Cancer Research Chemistry Cell Survival Antineoplastic Agents Apoptosis Breast Neoplasms Cell cycle General Biochemistry Genetics and Molecular Biology Cancer cell Cancer research Isoniazid MCF-7 Cells DNA fragmentation Immunogenic cell death Cytotoxic T cell Animals Humans MTT assay Female Fragmentation (cell biology) Reactive Oxygen Species Research Article Cell Proliferation |
Zdroj: | In Vivo |
Popis: | Background/Aim: Isoniazid is an antibiotic used for the treatment of tuberculosis. Previously, we found that the isoniazid derivative (E)-N’-(2,3,4-trihydroxybenzylidene) isonicotinohydrazide (ITHB4) could be developed as novel antimycobacterial agent by lead optimization. We further explored the ability of this compound compared to zerumbone in inhibiting the growth of MCF-7 breast cancer cells. Materials and Methods: Cytotoxicity was measured by the MTT assay and further confirmed via apoptosis, ROS, cell cycle, DNA fragmentation and cytokine assays. Results: ITHB4 demonstrated a lower IC(50 )compared to zerumbone in inhibiting the proliferation of MCF-7 cells. ITHB4 showed no toxicity against normal breast and human immune cells. Apoptosis assay revealed that ITHB4, at a concentration equal to the IC(50, )induces apoptosis of MCF-7 cells and cell cycle arrest at the sub-G1 and G(2)/M phases. ITHB4 triggered accumulation of intracellular ROS and nuclear DNA fragmentation. Secretion of pro-inflammatory cytokines induced inflammation and potentially immunogenic cell death. Conclusion: ITHB4 has almost similar chemotherapeutic properties as zerumbone in inhibiting MCF-7 growth, and hence provide the basis for further experiments in animal models. |
Databáze: | OpenAIRE |
Externí odkaz: |